More Detail to Be Made Public on FDA Advisory Panel Finances

The FDA is proposing to disclose a new detail in listing conflicts of interest for advisory committee members — the name of the company or institution involved — as the agency’s head recommends that officials minimize conflicts of interest on panels. Currently, the agency discloses only whether a panel member’s financial interest is associated with the sponsor, a competitor or another affected firm. Comments on the draft guidance are due June 21.
Washington Drug Letter